Fig. 4: SLC7A5 knockout LUSC cells harbor deficient mTORC1 signaling. | Oncogenesis

Fig. 4: SLC7A5 knockout LUSC cells harbor deficient mTORC1 signaling.

From: Targeting SLC7A5 in lung squamous cell carcinoma: implications for cancer metabolism shift and boron neutron capture therapy resistance

Fig. 4

A Gene set enrichment analysis (GSEA) of RNA-seq data assessing mTORC1 signaling-associated gene expression in wild-type H2170 (WT) versus its SLC7A5 knockout cells (SLC7A5-KO). B Gene set of the mTORC1 signaling pathway in wild-type H2170 (WT) versus its SLC7A5 knockout cells (KO) from RNA-seq data. C RT-qPCR analysis assessing mTOR pathway-related gene (AKT3 and RHEB) expression in wild-type H2170 and SLC7A5 knockout cells (KO1 and KO2). ***p < 0.001. D Scatter plot analysis assessing the correlation between SLC7A5 and RHEB expression in LUSC tumors from the TCGA-LUSC database. **p < 0.01. E Scatter plot analysis assessing the correlation of SLC7A5 with phospho-S6 (pS240S244 and pS235S236) protein expression in LUSC tumors from the TCGA-LUSC database. *p < 0.05. F RT-qPCR analysis (upper) assessing LC3B and SQSTM1 expression in H2170 in the presence or absence of rapamycin (RAPA, 20 μM) for one month. Immunoblotting analysis (lower) assessing LC3B-I and LC3B-II expression in wild-type (WT) H2170 and H2170-RAPA cells treated with or without chloroquine (CQ). **p < 0.01. G RT-qPCR (upper) and immunoblotting (lower) analysis assessing SLC7A5 expression in H2170 and H2170-RAPA cells. ***p < 0.001.

Back to article page